Clinical translation of carbon nanomaterials: the clinical translation paradox, regulatory barriers, and future pathways
- 27 August 2026
- journal article
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 18 (33) , 17523-17558
Abstract
Carbon nanomaterials face a clinical translation paradox where functional complexity conflicts with regulatory predictability. This review offers a practical roadmap for safer, more controllable, and clinically translatable carbon nanotechnologies.Keywords
Funding Information
- China Postdoctoral Science Foundation (2024M752238)
- China Postdoctoral Science Foundation (2025M771987)
- China Postdoctoral Science Foundation (GZC20251341)
- Natural Science Foundation of Sichuan Province (2025ZNSFSC1649)
- National Natural Science Foundation of China (82401144)
This publication has 231 references indexed in Scilit:
- Leveraging Oriented Lateral Walls of Nerve Guidance Conduit with Core–Shell MWCNTs Fibers for Peripheral Nerve RegenerationAdvanced Healthcare Materials, 2024
- Engineering Carbon Nanotube‐Based Photoactive COF to Synergistically Arm a Multifunctional Antibacterial HydrogelAdvanced Functional Materials, 2023
- Carbon Nanofiber in Regenerative Medicine2021
- Bone Tissue Engineering via Carbon‐Based NanomaterialsAdvanced Healthcare Materials, 2020
- C3N—A 2D Crystalline, Hole‐Free, Tunable‐Narrow‐Bandgap Semiconductor with Ferromagnetic PropertiesAdvanced Materials, 2017
- Toward Efficient Orange Emissive Carbon Nanodots through Conjugated sp2‐Domain Controlling and Surface Charges EngineeringAdvanced Materials, 2016
- Truly Fluorescent Excitation‐Dependent Carbon Dots and Their Applications in Multicolor Cellular Imaging and Multidimensional SensingAdvanced Materials, 2015
- Nitrogen‐Doped Porous Carbon Nanofiber Webs as Anodes for Lithium Ion Batteries with a Superhigh Capacity and Rate CapabilityAdvanced Materials, 2012
- Electrochemical Tuning of Luminescent Carbon Nanodots: From Preparation to Luminescence MechanismAdvanced Materials, 2011
- Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomesCancer, 1999